AstraZeneca Ends Phase Three Lung Cancer Drug Trial After Review

The decision was based on the recommendation of the Independent Data Monitoring Committee, which said volrustomig plus chemotherapy was unlikely to reach primary endpoints.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。